GLOSSARY

Molybdenum Requirement is the amount needed for dependent functions under specified conditions, with its establishment depending on essentiality evidence and the reference framework.

Molybdenum participates in molybdopterin-dependent enzymes, including pathways processing sulfite and purine compounds. Legumes, grains and nuts provide amounts that vary with soil. Kidneys regulate excretion, and acquired deficiency with ordinary eating is very rare. Roles of selected detoxification enzymes do not validate a general supplement detox claim; an additional performance benefit is not established for athletes whose diets already provide adequate supply.

Requirements vary with age, sex, life stage, absorption and some illnesses; population reference values are not identical personal prescriptions for athletes. Increased training can accompany greater food intake that supplies additional minerals. Before adding a supplement, assess actual eating, excluded food groups and documented losses rather than assuming the athlete label alone establishes a greater requirement for every element.

Intake, absorption and body status are distinct. An apparently adequate food record can coexist with poor uptake from intestinal disease or medicines, while one low-intake day does not establish clinical deficiency. Interpret repeated food records, longer-term patterns, symptoms and suitable markers together. Fatigue after one training session is not a specific diagnostic test for an individual mineral.

For molybdenum, assess food and all supplements alongside symptoms; the ingredient name on a product establishes neither need nor the cause of fatigue.

Deficiency involves inadequate supply with relevant consequences or validated evidence; insufficiency may describe intake or status below a reference, depending on the framework. Weakness, cramping and poor performance are nonspecific and can reflect sleep, energy, illness or training load. Assessment considers both the nutrient problem and its cause. Dietary improvement and treatment of underlying disease may need to proceed together.

Essentiality does not make any amount harmless. Chemical form, dose, duration, kidney or liver function and medicines affect risk. High intake and established toxicity are not identical, but overlapping supplements should be identified before symptoms occur. A therapeutic dose for a defined condition is not a routine recommendation for every athlete, and a larger intake does not necessarily produce a better outcome.

Inherited molybdenum cofactor deficiency is a specific metabolic disease, distinct from low dietary intake in a healthy athlete. Genetic disease and nutritional deficiency do not have one interchangeable supplement response. Excess exposure can also be harmful. Diagnosis, compound and route matter; doses discussed in medical or occupational contexts are not exercise-nutrition recommendations, and rare deficiency does not justify unrestricted intake.